Purple Biotech Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $2.4M
- Price
- $1.46
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.67%
- Volume
- 11.1K
About
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
Quick stats
Shares outstanding1.6M
Computed float130.5K
Float / shares8.0%
Cash runway (months)6.6
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001614744
Websitehttps://purple-biotech.com
AI Summary
AI-generated1/6
standardbullishearnings
Purple Biotech Reports Second Quarter 2026 Financial Results
Purple Biotech reported Q2 2026 net income of $0.4 million, reversing a net loss of $1.1 million in the prior-year period, primarily due to a non-cash gain from the revaluation of outstanding warrants.
The company released new preclinical data for IM1240, demonstrating an 8-fold longer half-life and 16-fold greater systemic exposure compared to non-capped variants, supporting a planned first-in-human study in 2027.
With a total cash position of $6.1 million as of June 30, 2026, management estimates the current runway extends through mid-2027 as it evaluates financing alternatives and strategic partnerships.
Red flags
- Net income driven by non-cash warrant revaluation
- Cash runway extends only to mid-2027